1. �й�ҽѧ��ѧԺ�Ͼ�Ƥ�����о���
2. �й�ҽѧ��ѧԺ����Э��ҽѧԺƤ�����о���

��ժҪ�� �������ע�������򵰰���׼����ԭ��������ȱ�ݲ��Ŀ���������ƣ����Ŷ������û��ƵĽ�һ����ʶ������ע�������򵰰��������ƴ�����Ƥ�����������֯������֢ҩ����鲡�ȼ�����֤ʵ��Ч�ã�����˻��������ʣ�����԰�ȫ�Ըߣ������Ժã���Ҳ��һЩ������Ӧ��Ŀǰ����ȱ����ȱ��������������������顣

Song Hao, Xu Xiulian. Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College; Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing 210042, China Corresponding author: Xu Xiulian, Email: xxlqjl@sina.com ��Abstract�� Intravenous immunoglobulin ��IVIG�� was initially approved as an alternative to antibodies in the treatment of primary immunodeficiency diseases. With further insights into its action mechanism, IVIG has been successfully applied to the treatment of bullous dermatoses, connective tissue diseases, severe drug eruptions, Kawasaki disease, etc. It has been proved that IVIG has good therapeutic effect and increases the survival of patients. Although IVIG is relatively safe and well tolerable, it has some adverse effects. Currently, lack of large-scale randomized controlled trials ��RCTs�� remains the biggest problem.